Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Oliver Sartor MD
Oliver Sartor MD Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · October 01, 2020

Pembrolizumab vs Single-Agent Chemotherapy for Advanced Pretreated Malignant Pleural Mesothelioma

Annals of Oncology

 

 Save  Recommend
 Share

Additional Info

Annals of Oncology
A Multicentre Randomised Phase III Trial Comparing Pembrolizumab vs Single-Agent Chemotherapy for Advanced Pre-Treated Malignant Pleural Mesothelioma: The European Thoracic Oncology Platform (ETOP 9-15) PROMISE-Meso Trial
Ann. Oncol 2020 Sep 22;[EPub Ahead of Print], S Popat, A Curioni-Fontecedro, U Dafni, R Shah, M O'Brien, A Pope, P Fisher, J Spicer, A Roy, D Gilligan, O Gautschi, E Nadal, WD Janthur, RL Castro, RG Campelo, S Rusakiewicz, I Letovanec, V Polydoropoulou, H Roschitzki-Voser, B Ruepp, A Gasca-Ruchti, S Peters, R Stahel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated